Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run
Rhea-AI Summary
Psyched Wellness (OTCQB: PSYCF) announced that its new product Calmer, a double-strength formula using the proprietary AME-1 extract, has sold out of the initial production run following strong early demand and positive consumer feedback. The company has initiated a new production run and plans to implement a double filtration process to improve flavor based on customer input. Updated restocking timelines and expanded distribution details will be provided as production advances. Management said it is scaling production to replenish supply and continues to focus on product portfolio expansion and distribution growth.
Positive
- Initial Calmer production run sold out after launch
- Company has initiated a new production run to meet demand
- Plan to add a double filtration process to improve flavor
- Management reports positive consumer feedback supporting market potential
Negative
- Calmer is currently out of stock until new production completes
- Adding double filtration may delay restocking and expansion timing
News Market Reaction – INFY
On the day this news was published, INFY declined 2.74%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing and commercializing products derived from the Amanita Muscaria mushroom, is pleased to announce a key commercial milestone for its newest product, Calmer. The Company has officially sold out of its initial production run following strong early demand and positive consumer feedback.
Newest Product: Calmer
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6579/280534_fa2860ab549bdae3_001full.jpg
Calmer, a new double strength formula made with Psyched Wellness' proprietary AME-1 extract, was developed to provide increased support for relaxation and everyday stress management. The Company is encouraged by the enthusiastic response from early consumers. The rapid sell-through reinforces the Company's confidence in the product's long-term market potential.
To meet growing demand, Psyched Wellness has already initiated a new production run, with efforts to implement a double filtration process to improve flavor following customer feedback. Updated timelines for restocking and expanded distribution will be shared as production advances.
Jeff Stevens, CEO of Psyched Wellness, commented:
"We're thrilled to see Calmer resonate so strongly with our customers. Selling out the first run is a meaningful milestone for the Company and a clear signal that our user community was looking for a stronger version of Calm to amplify their experience. We're moving quickly to scale production and ensure Calmer is back in stock as soon as possible."
Psyched Wellness remains focused on expanding its product portfolio, strengthening distribution channels, and delivering shareholder value as it advances its mission to bring innovative, mushroom-derived wellness products to market.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to researching and producing consumer packaged goods products derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.
Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the Company's production timelines, anticipated demand for CALMER, commercialization strategy, regulatory pathways, and expectations for future product availability. Forward-looking statements are based on management's current assumptions and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those projected. These risks include manufacturing or supply-chain challenges, regulatory developments, market conditions, and other factors described in the Company's public filings. Readers are cautioned not to place undue reliance on forward-looking statements. Psyched Wellness undertakes no obligation to update or revise any forward-looking information except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280534
FAQ
Why did Psyched Wellness (PSYCF) sell out of Calmer's first run?
When will Calmer be back in stock for PSYCF investors and customers?
What changes is Psyched Wellness (PSYCF) making to Calmer production?
Does the Calmer sell-out signal demand for other Psyched Wellness (PSYCF) products?
How did Psyched Wellness (PSYCF) describe Calmer's formulation?
Who can investors contact for more information about Psyched Wellness (PSYCF)?
